Marshall Wace’s Poseida Therapeutics, Inc. Common Stock PSTX Stock Holding History

Marshall Wace’s Portfolio PSTX Stock Details PSTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-146,232	Closed	-$1.4M	–	3207
2024 Q4	$1.4M	Buy	146,232 +106,039	+264%	+$553K	﹤0.01%	1576
2024 Q3	$115K	Buy	40,193 +29,655	+281%	+$91.8K	﹤0.01%	2359
2024 Q2	$30.8K	Buy	+10,538	New	+$28.8K	﹤0.01%	2467
2023 Q3	–	Sell	-40,760	Closed	-$71.7K	–	2790
2023 Q2	$71.7K	Sell	40,760 -407,985	-91%	-$1.04M	﹤0.01%	2357
2023 Q1	$1.38M	Sell	448,745 -62,659	-12%	-$376K	﹤0.01%	1658
2022 Q4	$2.71M	Buy	+511,404	New	+$2.34M	0.01%	1556

Other funds holding PSTX

DekaBank Deutsche Girozentrale Frankfurt, Germany $60.6B AUM 23.27% 1-Year Est. Return

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Marshall Wace's PSTX Position: Q1 2025 in Review

Marshall Wace sold out of Poseida Therapeutics, Inc. Common Stock (PSTX) in Q1 2025, closing a stake of 146,232 shares — an estimated $1.4M sold.

Marshall Wace first reported a position in PSTX in Q4 2022 and held it in 6 quarters. The position peaked at $2.71M in Q4 2022. 1 fund tracked by Wall St. Rank holds PSTX as of Q1 2025.

Marshall Wace reported no remaining Poseida Therapeutics, Inc. Common Stock position as of Q1 2025 after selling out during the quarter.
Marshall Wace sold 146,232 Poseida Therapeutics, Inc. Common Stock shares in Q1 2025, an estimated $1.4M.
Marshall Wace first reported a position in Poseida Therapeutics, Inc. Common Stock in Q4 2022 and held it in 6 quarters.
Marshall Wace's Poseida Therapeutics, Inc. Common Stock position peaked at $2.71M in Q4 2022.
1 fund tracked by Wall St. Rank held Poseida Therapeutics, Inc. Common Stock as of Q1 2025.

Based on Marshall Wace's 13F filing for Q1 2025, filed 15 May 2025.